Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

By James C. Yao, A. Phan, D. Chang, R. Wolff, K. Hess, Sanjay Gupta, C. Jacobs, J. Mares, A. Landgraf, A. Rashid and 1 more. Journal of Clinical Oncology, 2008

634 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/f31f884b0361a9bee12be583020a926a395a9159

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Law
2. M. Cukier
3. J. Hallet
4. Ning Liu
5. R. Saskin

Citations in the corpus

• Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes (2015, background): “Recently, international collaborations have resulted in promising randomized controlled trials that revealed significant benefits of somatostatin analog and targeted biologic therapies, which offer NET patients improved progression-free survival.(8,9) However, much remains to be learned about these ”